Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (University of Zurich)
- Development stage
- Unknown
- Lead developer
- University of Zurich
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplantation (FMT) is an investigational biological therapy being evaluated by the University of Zurich for its potential to treat metabolic and cardiovascular diseases. The procedure involves the transfer of a processed suspension of fecal matter from a healthy, screened donor into the gastrointestinal tract of a recipient—specifically patients with type 2 diabetes mellitus and stable coronary artery disease—via colonoscopy. The therapeutic rationale is based on the 'gut-heart' axis, where gut dysbiosis is thought to drive systemic inflammation and metabolic dysfunction. By restoring a healthy and diverse microbial community, the treatment aims to modulate the gut-brain-liver axis, improve insulin sensitivity, and reduce the inflammatory milieu associated with atherosclerosis.
- Other names
- Fecal Microbiota TransplantationFMTFecal Microbiota TransferFecal Transplant
Beyond the preview
Go deeper on fecal microbiota transplantation (University of Zurich).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (University of Zurich).